CASE REPORT Open Access



Posterior cerebral fossa medulloepithelioma: report of a case

Nezha Oumghar^{1*}, Fatima Ezzahra Hazmiri², Abdelhamid El Omrani¹, Hanane Rais² and Mouna Khouchani¹

Abstract

Background: Medulloepithelioma is a rare primitive neuroectodermal tumor of the central nervous system, usually developing in childhood. Due to its rarity, the optimal management is still unknown. The prognosis is poor, especially when resection is incomplete. Adjuvant radiochemotherapy is often indicated.

Case presentation: We report a rare case of infratentorial medulloepithelioma in a 3 year old girl. She presented symptoms of increased intracranial pressure. On examination, she had coordination problems, ptosis and exotropia of the right eye. Magnetic resonance imaging demonstrated a large cerebellar vermix tumor. Immunohistochemistry revealed a diffuse positivity for Vimentin and focal positivity for the epithelial membrane antigen, but Glial Fibrillary Acidic Protein and Synaptophysin were negative, the MIB-1 antibody was very high. She received postoperative craniospinal irradiation and died 7 months later.

Conclusion: We describe the features (epidemiological, clinical, histological, immunohistochemical and therapeutic outcomes) of our case and confront it to literature data.

Keywords: Medulloepithelioma, Primitive neuroectodermal tumor, Infratentorial, Radiotherapy

Background

Medulloepithelioma of the central Nervous System (CNS) is an uncommon primitive neuroectodermal tumor (PNET), characterized by a highly malignant behavior [1]. It is a rare tumor usually located in the supratentorial area [2], with the peak incidence between 6 months to 5 years of age. We report a case of infratentorial medulloepithelioma in a 3-year-old girl.

Case presentation

A 3 year-old girl was admitted to the emergency department with intracranial hypertension picture without fever of 30 days duration. On examination, she had coordination problems, ptosis and exotropia of the right eye. Her vitals were stable. Brain magnetic resonance imaging (MRI) showed a large cerebellar vermis lesion compressing the 4th ventricle with surrounding edema and triventricular hydrocephalus, the mass demonstrated a heterogeneous low signal on T2-weighted (Fig. 1). A subtotal resection and ventriculoperitoneal shunt hydrocephalus was

VI University Hospital, Marrakech, Morocco Full list of author information is available at the end of the article



performed. Histology characteristically shows a Highly cellular embryonal tumor composed of small size cells with little perinuclear cytoplasm, and Hyperchromatic nuclei with granular chromatin. Mitotic figures are abundant. it is also characterized by the presence of islets of hyaline cartilage and tumoral necrosis. Immunohistochemistry revealed diffuse positivity for Vimentin, while expression of synaptophysin was absent. It showed focal positivity for the Epithelial Membrane Antigen (EMA), for AC anti-EMA and for AC anti- PS100, while the Glial Fibrillary Acidic Protein (GFAP) was negative. MIB-1 labeling was very high, exceeding 50%. The diagnosis of medulloepithelioma was retained (Fig. 2). The evolution has been marked by the deterioration of neurological status, she had corticicosteroide bolus without improvement of symptoms, she received a craniospinal irradiation: The patient underwent a planning CT in dorsal decubitus position under sedation, The treatment was delivered via 2 lateral fields to the head and 2 direct posterior fields to upper and lower spine, The junctions between the 3 fields moved caudally every week, 36Gy in 2-Gy fractions were delivered over 4 weeks to the craniospinal axis, with a boost to the posterior fossa, Radiotherapy was well tolerated with a spectacular improvement of symptoms, during radiotherapy. Neurological condition

^{*} Correspondence: nezha.oumghar@gmail.com ¹Radiotherapy department – Oncology and hematology center, Mohammed



Fig. 1 The axial T1 (a), T2 W/FLAIR (b) image shows cerebellar vermis lesion that was hypointense on T1WI and heterogeneous on T2WI, vith perilesional edema, and triventricular hydrocephalus

deteriorated 3 months after the end of radiotherapy and survival was 6 months.

Discussion

The medulloepithelioma of the central nervous system is a rare tumor representing 1.5% of primary tumors of the CNS [3], with a peak incidence between 6 months and 5 years of age [4], few cases in adolescents are reported in the literature. No specific sex predilection [2, 5].

Medulloepitheliomas are mostly supratentorial lesions commonly found in the periventricular location [6]. They are mostly involving in order of frequency: temporal, parietal, occipital and frontal lobes. Other locations have been reported in the literature such as in infratentorial: at the level of the brainstem [4], or cerebellar pontine angle [7]. The intraorbital location is quite special because of the origin remains unexplained and good prognosis after enucleation of the eye [4].

The clinical picture is nonspecific and is based on the seat of the lesion. Most often, it is a syndrome of intracranial hypertension with or without a neurological deficit. The mean duration of symptoms was 6 weeks [8].

Appearances on MRI are very variable, they are typically iso to hypointense with grey matter on T1 weighted imaging and iso to hypointense on T2 weighted imaging, 95% of tumours will show contrast enhancement, particularly of the solid elements [9]. Pre-operative imaging with MRI is important in order to assess CSF dissemination of tumour.

The diagnosis of medulloepithelioma can be confusing with other primitive neuroectodermal tumors (PNET), such as medulloblastoma, neuroblast, the ependymoblastoma, teratoma or some glial tumors [10]. The predominant




Fig. 2 Histological and Immunohistochemical findings. **a:** Malignant tumor proliferation with round cells HE x10 **b:** Tubular structures HEx20 **c:** Intense and diffuse membrane expression of vimentin HEx10

structure resembles that of the epithelium of the primitive neural tube. Besides the beaches of neuroepithelial progenitor cell, papillary and / or tubular formations and neuroepithelial cells arranged in a pseudo-epithelium laminate are found [10, 11]. The tumor cells are relatively large, cylindrical or polygonal and have scant eosinophilic cytoplasm. The nuclei are oval or rounded vary in size with a granular chromatin with many nucleoli [12]. Figures mitotic often are many particularly at the level of cells adjacent to the luminal surface [13]. The latter is covered by a PAS positive material simulating internal limiting membrane [12]. The outer surface of these tubes is limited by a basement membrane or outer limiting membrane resting on a loose connective tissue stroma. Neuronal maturation areas, glial, ependymal, or even mesenchymal are reported. Histochemical techniques and immunohistochemical provided an additional argument in differentiation potential of this neoplasm. Thus, the ependymal and astroglial elements have positive immunoreactivity to GFAP and PS100, and neural elements have a positive immunoreactivity for synaptophysin. An important fact is the rather frequent positive immunoreactivity to vimentin [4], which is the first protein filamentary intermediate expressed at an early stage of development of the neural tube mammals. Finally, the beaches of necrosis and hemorrhage can be found. This tumor has an aggressive local infiltrative extension and a tendency to spread along drainage ways CSF [14]. Some authors have reported metastases extra Nevrax.

The prognosis of these tumors is generally poor due to their relative radioresistance and their inexorable tendency to recurrence and spread to intra-and extraaxial [15]. The mean survival is estimated by the literature to 5 months [4]. However very long survival exceeding 13 years have been reported, In a recent review of the literature [2, 15], 44 cases of medulloepithelioma were published by authors from different interest poles [16], according to this study, the best treatment of these lesions appears is the most complete surgical excision associated with extensive entire neuraxis radiotherapy, the dose prescription for patients with localised PNETs should be 35 Gy in 21 daily fractions, followed by a second radiotherapy phase of 20 Gy in 12 fractions to the posterior fossa or otherwise to the primary tumour (if biopsied only) or any postoperative residual tumour. Adjuvant chemotherapy can have a beneficial effect for some authors but the systematic indication remains controversial. The best results obtained in this type of tumor may be related to some factors predictive of good prognosis: Supratentorial location, gross total resection, absence of cerebrospinal fluid (CSF) dissemination, and postoperative aggressive chemoradiotherapy [2, 14, 17, 18].

Table 1 summarizes the treatments received and the survival in cases of medulloepithelioma of the posterior

Table 1 Characteristics of the published cases of posterior cerebral fossa medulloepithelioma

cerebiai 1033a medalioepitilelloma						
Case	Age	Dissemination	Surgery	RT	CT	Survival
Best (1974) [19]	2 years	No	Biopsy	No	No	2 weeks
Pollak et Friede (1977) [12]	15 months	NR	PR	Yes	No	11 months
Bonnin et al. (1984) [20]	15 months	LCR	PR	No	No	4 months
Molloy et al. (1996) [4]	15 months	No	TR	Yes	Yes	> 13 years
Khoddami et Becker (1997) [21]	30 months	NR	PR	Yes	No	11 months
Scharma et al. (1998) [22]	9 months	No	TR	Yes	No	NR
Vincent et al. (2002) [10]	3 months	NR	TR	No	No	> 7 years
Syal et al. [7]	5 years	LCR	TR	Yes	Yes	< 1 month
Our patient (2014)	3 years	No	PR	Yes	No	6 months

RT radiotherapy, CT chemotherapy, PR partial resection, TR total resection, LCR cerebrospinal fluid, NR non reported

cerebral fossa published in the literature [4, 7, 10, 12, 19-22].

Necessity to look for alternative molecular markers and directed treatment similar to INI-1 in atypical teratoid rhabdoid tumors is emerging. In recent times, hTERT oncogene amplification has been demonstrated in a proportion of embryonal tumors, particularly medulloblastomas, as well as, medulloepitheliomas [23], a correlation with survival has been suggested and whether this might emerge as a molecular marker in future remains to be seen.

Conclusion

The medulloepithelioma is the most undifferentiated and malignant of PNET. It affects young children and can sit anywhere in the CNS, usually in periventricular. Clinical and imaging are not specific. Only histology with immunohistochemistry confirms the diagnosis by showing the typical appearance, with often positive immunoreactivity to vimentin. The prognosis may be better if we can make a complete surgical resection and radiotherapy.

Informed consent

Written informed consent was obtained from the parents of patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Patient perspective

Inappropriate.

Abbreviations

CNS: Central Nervous System; CSF: Cerebrospinal fluid; EMA: Epithelial Membrane Antigen; GFAP: Glial Fibrillary Acidic Protein; PNET: Primitive neuroectodermal tumor

Acknowledgements

We thank the family of the patient for cooperation.

Funding

The authors received no specific funding for this study.

Availability of data and materials

Data and materials mentioned in the report are available on request from the authors.

Authors' contributions

The authors participated in the management of the patients and the writing of the manuscript. The final version has been reviewed and approved by all authors.

Ethics approval and consent to participate

Not applicable.

Consent for publication

The authors have obtained written informed consent from the parents (legal guardian) for publication of this case report.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Radiotherapy department – Oncology and hematology center, Mohammed VI University Hospital, Marrakech, Morocco. ²Pathology department – Arrazi Hospital, Mohammed VI University Hospital, Marrakech, Morocco.

Received: 8 June 2017 Accepted: 13 November 2017 Published online: 21 November 2017

References

- Gessi M, Giangaspero F, Lauriola L, et al. Embryonal tumors with abundant neuropil and true rosettes: a distinctive CNS primitive neuroectodermal tumor. Am J Surg Pathol. 2009;33(2):211–7.
- Lolova I, Bojinov S, Ivanova A. Cerebral medulloepithelioma. Histological and histochemical study of a case. J Neurol Sci. 1972;15:173–82.
- 3. Becker LE, Hinton D. Primitive neuroectodermal tumors of the central nervous system. Hum Pathol. 1983;14:538–50.
- Molloy PT, Yachnis AT, Rorke LB, Millar WS, et al. Central nervous system medulloepithelioma: a series of eight cases including two arising in the pons. J Neurosurg. 1996;84:430–6.
- La Spina M, Pizzolitto S, Skrap M, et al. Embryonal tumor with abundant neuropil and true rosettes. A new entity or only variations of a parent neoplasms (PNETs)? This is the dilemma. J Neuro-Oncol. 2006;78:317–20.
- Troost D, Jansen GH, Dingemans KP. Cerebral medulloepithelioma-electon microscopy and immunohistochemistry. Acta Neuropathol. 1990;80:103–7.
- Syal R, Reddy SJ, Kumar R, Tyagi I, Krishnani N, et al. Unusual clinical and MRI features of a cerebellopontine angle medulloepithelioma. Pediatr Neurosurg. 2006;42:299–303.
- Leland Albright A, Wisoff JH, Zeltzer P, Boyett J, Rorke LB, Stanley P, Russel Geyer J, Milstein JM. Prognostic factors in children with supratentorial primitive neuroectodermal tumors. Pediatr Neurosurg. 1995;22:1–7.
- Lawandy S, Hariri OR, Miulli DE, et al. Supratentorial primitive neuroectodermal tumor in an adult: a case report and review of the literature.
 J Med Case Rep. 2012;6:361.

- Vincent S, Dhellemmes P, Maurage CA, Soto-Ares G, Hassoun J, Ruchoux MM. Intracerebral medulloepithelioma with a long survival. Clin Neuropathol. 2002;21(5):197–205.
- Ceccom J, Bourdeaut F, Loukh N, et al. Embryonal tumor with multilayered rosettes: diagnostic tools update and review of the literature. Clin Neuropathol. 2014;33(1):15–22.
- Pollak A, Friede RL. Fine structure of medulloepitheliome. J Neuropathol Exp Neurol. 1977;36:712–25.
- Nakamura Y, Becker LE, Mancer K, Oilepsie R. Peripheral medulloepithelioma. Acta Neuropathol. 1982;57:137–42.
- Karch SB, Urich H. Medulloepithelioma: definition of an entity. J Neuropathol Exp Neurol. 1972;31:27–53.
- Matsumoto M, Horiuchi K, Sato T, Oinuma M, Suzuki T. Cerebral medulloepithelioma with long survival. Neurol Med Chir (Tokyo). 2007;47:428–33.
- Bouhoula A, et al. Central nervous system medulloepithelioma. A report of three cases. J Neuchi. 2010, 56;(5):395

 –400.
- Norris LS, Snodgrass S, Miller DC, Wisoff J, Garvin J, Rorke LB, et al. Recurrent central nervous system medulloepithelioma: response and outcome following marrow-ablative chemotherapy with stem cell rescue. J Pediatr Hematol Oncol. 2005;27:264–6.
- Regina I, et al. Outcome and prognostic factors for children with Supratentorial primitive Neuroectodermal tumors treated with Carboplatin during radiotherapy: a report from the Children's oncology group. Pediatr Blood Cancer. 2015;62:776–83.
- Best PV. Posterior fossa medulloepithelioma; report of a case. J Neurol Sci. 1974;22:511–8.
- Bonnin JM, Rubinstein LJ, Palmer NF, Beckwith JB. The association of embryonal tumor originating in the kidney and in the brain. A report of seven cases. Cancer. 1984;54:2137–46.
- 21. Khoddami M, Becker LE. Immunohistochemistry of medulloepithelioma and neural tube. Pediatr Pathol Lab Med. 1997;17:913–26.
- Sharma MC, Mahapatra AK, Gaikwad S, Jain AK, Sarkar C. Pigmented medulloepithelioma: report of a case and review of the literature. Childs Nerv Syst. 1998;14:74–8.
- Fan X, Wang Y, Kratz J, Brat DJ, Robitaille Y, Moghrabi A, et al. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol. 2003;162:1763–9.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

